dc.contributor.author | Koksal, Iftihar | |
dc.contributor.author | Yilmaz, Gurdal | |
dc.contributor.author | Unal, Serhat | |
dc.contributor.author | Zarakolu, Pinar | |
dc.contributor.author | Korten, Volkan | |
dc.contributor.author | Mulazimoglu, Lutfiye | |
dc.contributor.author | Tabak, Fehmi | |
dc.contributor.author | Mete, Birgul | |
dc.contributor.author | Oguz, Vildan Avkan | |
dc.contributor.author | Gulay, Zeynep | |
dc.contributor.author | Alp, Emine | |
dc.contributor.author | Badal, Robert | |
dc.contributor.author | Lob, Sibylle | |
dc.date.accessioned | 2019-12-10T11:12:24Z | |
dc.date.available | 2019-12-10T11:12:24Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 0305-7453 | |
dc.identifier.uri | https://doi.org/10.1093/jac/dkw574 | |
dc.identifier.uri | http://hdl.handle.net/11655/15027 | |
dc.description.abstract | Objectives: To describe the epidemiology and susceptibility of pathogens (including ESBL producers) from hospital-acquired (HA) versus community-acquired (CA) urinary tract infections (UTIs) and ICU-versus non-ICU-associated intra-abdominal infections (IAIs) in Turkey as a part of the SMART study. Methods: For this report, Gram-negative pathogens (363 from UTIs and 458 from IAIs) were collected in 2011 and 2012 at six hospitals in Turkey. HA versus CA UTIs and ICU-versus non-ICU-associated IAIs were compared for the species isolated, percentage of ESBL-positive isolates by species and susceptibility for overall and individual Gram-negative species. Results: Escherichia coli was the most common pathogen identified in HA (40.2%) and CA (73.9%) UTIs and ICU-associated (25.8%) and non-ICU-associated (43.3%) IAIs. The rate of ESBL-positive E. coli was significantly higher in HA than in CA UTIs (50.5% versus 38.2%, P < 0.001) and in non-ICU-associated than in ICU-associated IAIs (52.5% versus 29.2%, P = 0.029). Of the drugs studied, only amikacin was active against >= 90% of pathogens in UTIs, while ertapenem, imipenem and amikacin were active against >= 90% of E. coli; and imipenem, amikacin and cefoxitin were active against >= 90% of Klebsiella pneumoniae in IAIs. Conclusions: Our findings demonstrated that E. coli continues to be the principal pathogen of UTIs and IAIs in Turkey. Along with a high rate of ESBL-positive isolates, high antimicrobial resistance among Gram-negative bacilli from either UTIs or IAIs was noted particularly in the case of HA UTIs and ICU-associated IAIs, with a higher likelihood of carbapenem-or amikacin-based therapy to provide the broadest activity against bacterial pathogens. | |
dc.language.iso | en | |
dc.publisher | Oxford Univ Press | |
dc.relation.isversionof | 10.1093/jac/dkw574 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Infectious Diseases | |
dc.subject | Microbiology | |
dc.subject | Pharmacology & Pharmacy | |
dc.title | Epidemiology And Susceptibility Of Pathogens From Smart 2011-12 Turkey: Evaluation Of Hospital-Acquired Versus Community-Acquired Urinary Tract Infections And Icu- Versus Non-Icu-Associated Intra-Abdominal Infections | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Journal Of Antimicrobial Chemotherapy | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 72 | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 1364 | |
dc.identifier.endpage | 1372 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |